10X Genomics (NasdaqGS:TXG) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAdam Taich - CFOCasey Woodring - VP of Equity ResearchCassie Corneau - Senior Director and Head of Investor Relations and Strategic FinanceDan Arias - Managing DirectorDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorSalem Salem - VP of Equity ResearchSerge Saxonov - Co-Founder and CEOSubbu Nambiar - Managing DirectorT ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $20.1 million, up 16% sequentially and 30% year-over-year, exceeding guidance [20] - Full year 2025 total revenue was $70.6 million, a 22% increase year-over-year [20] - Annual contract value plus royalties reached $83.6 million, a 28% year-over-year increase, marking a new record [21] - Remaining performance obligations (RPO) totaled $117 million, representing a 32% year-over-year increase, another record high [21] - Non-GAAP gross profit for Q4 was $18.5 million, with a gross margin of 92% [22] - Non-GAAP operating loss for Q4 was $2.2 million, above the top end of guidance [24] - GAAP net loss for Q4 was $8.5 million, with a diluted net loss per share of $0.19 [25] Business Line Data and Key Metrics Changes - The royalty stream increased by 50% year-over-year, with Q4 setting a new record [20] - FlexGen, an AI-driven smart NoC IP product, saw strong customer adoption, licensed for over 30 production device deployments [11] - Ncore, a cache coherent interconnect IP product, also experienced strength in licensing across various edge and server applications [12] Market Data and Key Metrics Changes - The largest impacts on revenue were seen in enterprise computing, automotive, and consumer electronics markets [7] - The number of large royalty reporters tripled in the last two years, indicating a diversified customer base [20] Company Strategy and Development Direction - The acquisition of Cycuity enhances Arteris' product portfolio, focusing on semiconductor cybersecurity assurance [8] - The company aims to address market concerns about increasing cybersecurity threats in semiconductor designs [9] - Arteris is positioned to support semiconductor applications in the AI era across various sectors, including automotive and aerospace [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, expecting to report a non-GAAP operating profit as early as Q4 2026 [28] - The company anticipates continued strong demand for its products driven by the rise of AI and efficient data movement in semiconductors [7] Other Important Information - Free cash flow was positive at $3 million for Q4 and $5.3 million for the full year [26] - The company ended the year with $59.5 million in cash and no financial debt [26] Q&A Session Summary Question: Cross-sell opportunities and customer segments - Management highlighted that hardware security assurance is a growing issue, opening significant cross-sell opportunities across various semiconductor companies [30][31] Question: NXP's expanded use of Arteris solutions - Management confirmed that NXP is now using four solutions, indicating increased interest in deploying a complete suite of offerings [34][35] Question: Strength in royalties and market segments - Management noted that the growth in royalties is attributed to both customer diversification and the increase in large royalty reporters across various segments, particularly automotive [37][38] Question: Impact of security acquisition on P&L - Management clarified that approximately $7 million of the projected revenue for 2026 is expected from the Cycuity acquisition, with a slight contribution to operating loss anticipated [45][46]

Financial Data and Key Metrics Changes - The company reported $166 million in revenue for Q4 2025, representing a 1% increase year-over-year and exceeding the high end of guidance [20][21] - Full-year revenue for 2025 was $599 million, excluding $44 million from patent litigation settlements [6][20] - Gross margin improved to 68% in Q4 2025 from 67% in the prior year, driven by lower inventory write-downs and reduced royalty costs [22] Business Line Data and Key Metrics Changes - Total consumables revenue increased by 6%, with single-cell consumables revenue up 3% and spatial consumables revenue up 14% [21] - Single-cell consumables volumes grew at a double-digit rate each quarter, primarily due to the adoption of the lower-cost FLEX assay [7][21] - Instrument revenue declined by 36%, with Chromium instruments down 44% and spatial instruments down 30% [21] Market Data and Key Metrics Changes - Revenue from the Americas declined by 6%, while EMEA and APAC regions grew by 7% and 9%, respectively [22] - The Americas faced challenges due to a subdued funding environment, while EMEA benefitted from late-quarter orders [22] Company Strategy and Development Direction - The company aims to leverage advancements in AI and biology measurement technologies to drive growth, focusing on large-scale studies and translational research [12][14] - Plans to enhance clinical applications of single-cell and spatial analysis through collaborations with academic medical centers [17][49] - The company is committed to continuous innovation and expects 2026 to be a pivotal year for new product capabilities [18] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging operating environment in 2025, with subdued customer spending and ongoing funding uncertainties impacting purchasing decisions [6][19] - Despite these challenges, the company is optimistic about future growth driven by strong demand for its solutions and a solid financial position [11][19] - The outlook for 2026 includes revenue guidance of $600 million to $625 million, reflecting a stable funding environment and anticipated growth in consumables [24] Other Important Information - The company increased its cash balance by over $100 million year-over-year, reflecting disciplined cost management [11][23] - The launch of the FLEX APEX assay is expected to drive significant adoption and new applications in the single-cell market [9][41] Q&A Session Summary Question: Can you comment on ordering patterns and expectations for academic and pharma? - Management indicated that the environment remains steady but cautious, with ongoing uncertainty in academic funding impacting customer sentiment [30] Question: Was volume growth enough to offset pricing in single-cell consumables? - Management noted that in Q4, single-cell consumables saw over 30% volume growth, contributing to overall revenue growth despite pricing pressures [36] Question: What are the expectations for the clinical translational space? - The company is excited about future clinical applications and is pursuing a hybrid strategy to enable clinical evidence generation while supporting existing customers [49] Question: How is the company addressing competitive dynamics? - Management expressed confidence in their competitive position, highlighting continuous innovation and the strong performance of the Xenium platform [77] Question: What are the plans for cash generated in 2026? - The company aims to maintain a strong balance sheet to pursue strategic investments and opportunities as they arise [62]

Bridgeline Digital (NasdaqCM:BLIN) Q1 2026 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAri Kahn - President and CEOThomas Windhausen - CFOConference Call ParticipantsCasey Ryan - Research AnalystOperatorGood day, everyone, and welcome to the Bridgeline Digital First Quarter 2026 earnings call. At this time, all participants are placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to y ...

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [14] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control, with ongoing enrollment in the Australian oncology trial [5] - The second cohort of the oncology trial has seen two patients treated with Hemopurifier, with a third patient expected to be treated by the end of February [6][7] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for recruitment [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve immune response against tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [5][10] - Aethlon Medical is also exploring the potential of the Hemopurifier in treating conditions beyond oncology, including Long COVID and other diseases associated with extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the Australian oncology trial and the potential for the Hemopurifier to be integrated into oncology units and infusion centers, reducing invasiveness for patients [22][24] - The company is committed to cost containment while advancing its research and development efforts, particularly in the context of Long COVID [26] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal, indicating the company's commitment to transparency and scientific rigor [10] - The next earnings call for the fiscal fourth quarter is scheduled to coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - Management confirmed that participants in Cohort 2 will receive two Hemopurifier treatments, maintaining the same follow-up period as Cohort 1 [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system is expected to simplify the administration of Hemopurifier treatments, making it less invasive for patients and easier for hospital staff [22][24] Question: Cost-effective approach in R&D - Management emphasized the importance of cost containment while advancing research, focusing on in-house work and limiting external lab involvement [26] Question: Timeline for Data Safety Monitoring Board's decision - Management anticipates a decision from the Data Safety Monitoring Board on whether to advance to the third cohort on the same day or the next business day after the meeting [34] Question: Need for Cohort 3 - Management believes it is essential to conduct Cohort 3 to fully assess the efficacy of three treatments, based on historical data suggesting that more treatments may yield better results [60] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company will need to conduct safety tests and treatments before integration with the Hemopurifier [45]

Alliance Entertainment (NasdaqCM:AENT) Q2 2026 Earnings call February 12, 2026 04:30 PM ET Speaker3Greetings, and welcome to Alliance Entertainment's second quarter fiscal year 2026 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I will now pass the call over to Paul Kuntz, a member of Alliance Entertainment's IR team at RedChip. Paul? Pardon me on ...

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker14Ladies and gentlemen, good afternoon, and welcome to the Dexcom fourth quarter and fiscal year 2025 earnings release conference call. My name is Abby, and I will be your operator today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star one on your touchtone phone. As a reminder, the ...

Expedia Group (NasdaqGS:EXPE) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker9Hello, everyone. Thank you for joining us, and welcome to the Expedia Group Q4 2025 financial results webcast. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, press star one again. For opening remarks, I will now hand the call over to Rob Bevegni, VP of Investor Relations. Please g ...

Financial Data and Key Metrics Changes - Revenues for Q4 2025 were $4.9 million, a significant decrease from $31 million in Q4 2024, primarily due to lower unit sales [13] - Gross profit for Q4 2025 was $1.9 million, or 38.8% of revenues, down from $7.1 million, or 54.2% in Q4 2024, driven by lower sales and higher servicing costs [14] - For the full year 2025, revenues were $27.5 million, compared to $41.8 million in 2024, reflecting a decrease in unit sales [15] - The net loss for 2025 was $7.7 million, or a loss of $0.47 per share, compared to a net income of $6.6 million, or $0.41 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - The company shipped 14 units in Q4 2025, with 8 in the U.S. and 6 internationally, but did not include sales to its largest customer [24] - The Fair Deal Agreement program saw substantial year-over-year utilization increases, with treatments up more than eightfold and the number of patients treated increasing by over 250% in 2025 [7] Market Data and Key Metrics Changes - International sales were strong in Q4 2025, with shipments to China and a growing demand in Asia, particularly in Taiwan and South Korea [8][28] - The company expects international markets to remain a significant part of its growth strategy, with Brazil and the Middle East also showing potential [29] Company Strategy and Development Direction - The introduction of new CPT codes for SRT and IG-SRT technologies is expected to enhance physician reimbursement and support broader adoption of non-invasive treatments [4] - The company aims to achieve full-year profitability in 2026, supported by a diversified customer base and expanding international opportunities [9] - A disciplined approach to scaling the sales organization is being implemented, with plans to hire additional sales representatives to enhance market education and lead conversions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with improved clarity and control over the business, emphasizing the positive impact of new reimbursement codes [20] - The company is focused on converting interest into system placements as the year progresses, with expectations for Q1 revenues to exceed Q4 levels [19] Other Important Information - The company ended 2025 with $22.1 million in cash and cash equivalents, with no outstanding debt, indicating a strong balance sheet [18] - Research and development expenses for 2025 increased to $7.8 million, reflecting higher costs related to billing and reimbursement efforts [17] Q&A Session Summary Question: Does the revenue growth guidance for Q1 assume no contribution from the largest customer? - Management confirmed that projections for 2026 exclude expectations from the largest customer, and any contribution from them would be considered upside [24] Question: What is the status of the TDI program and expected FDA approval? - Management indicated ongoing efforts with the FDA but could not provide a timeline for approval [26] Question: What is the demand outlook internationally for 2026? - Management highlighted strong demand in China and growth in Taiwan, with expectations for expansion in South Korea, Japan, and potential entry into Brazil and the Middle East [28][29] Question: How has the reaction to reimbursement affected system mix and financing options? - Management noted a shift towards outright purchases and leasing options due to guaranteed reimbursements, with a stronger focus on SRT products [38][40] Question: What is the outlook for service revenue? - Service revenue remains consistent at about 10% of total revenue, with no expected changes [48]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $16 million, a 4% increase year-over-year, while full-year revenue reached $56.7 million, reflecting a 10% growth [3][17] - Gross profit for Q4 was $13.8 million, an 8% increase, with gross margin rising to 86% from 83% a year ago [19] - Net loss for Q4 was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in Q4 2024 [21] Business Line Data and Key Metrics Changes - U.S. revenue was $14.9 million in Q4 2025, a 4% increase, with revenue units totaling 478, up from 460 in the prior year [17] - European revenue increased to $1.1 million, a 10% rise, with revenue units growing to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only 1% penetration, indicating significant growth potential [5] - The initiation of the BENEFIT-HF trial could expand the addressable market to approximately $30 billion if successful [12] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [6] - Transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, effective January 1, 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute and drive growth, despite a natural ramp-up period for new sales representatives [6][15] - The company anticipates total revenue for 2026 to be between $63 million and $67 million, with a gross margin of 84% to 86% [23] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and increase access to additional capital [14][22] - A new Chief Human Resources Officer was appointed, indicating ongoing organizational development [16] Q&A Session Summary Question: On the BENEFIT-HF trial strategy and revenue generation - Management indicated that the trial will involve a mix of existing and new commercial sites, with expected revenue from approximately 1,600 to 1,700 devices sold during the trial [26][28] Question: Growth of active accounts in Q4 - Management noted that while there was a net addition of accounts, the focus remains on deepening existing relationships, with expectations of adding around three active territories quarterly in 2026 [30][31] Question: Impact of the Category I code on treatment barriers - Management reported positive early signs of improved prior authorization approvals and expects this trend to continue as the transition progresses [36][39] Question: Path to profitability and cash management - The company has sufficient cash reserves and access to additional capital, with a focus on driving sales productivity to achieve profitability [72][74]